Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre‐exposure COVID‐19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients
Internal Medicine Journal · 2025
DOI: 10.1111/imj.70179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Wai H Lim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Kidney Transplantation, COVID-19, Pancreas Transplantation, Pre-Exposure Prophylaxis. Die Arbeit nennt 17 Literaturangaben. Gefördert von: AstraZeneca Australia.
Abstract (Originalsprache)
The COVID‐19 pandemic resulted in high mortality rates in immunocompromised people, especially those who have received solid organ transplants. In this cohort of 540 transplant recipients who received tixagevimab/cilgavimab (Evusheld®) in Australia and New Zealand between January 2022 and January 2023, 11 (2%) Evusheld®‐treated recipients experienced moderate to severe COVID‐19 infection, with two deaths from COVID‐19 pneumonitis. Less than 0.5% experienced adverse events from Evusheld®. Prophylactic monoclonal antibody therapy may be considered an important adjunct to vaccination among immunocompromised patients to prevent severe infection during future viral outbreaks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
- School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.
- Medical School, University of Western Australia, Perth, Western Australia, Australia.
- Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
- Department of Renal Medicine, Auckland City Hospital, Auckland, New Zealand.
- Department of Medicine, Auckland University, Auckland, New Zealand.
ORCID-Profile: Germaine Wong
Förderung
- AstraZeneca Australia
Zitieren
APA
Lim, W. H., Wang, J., Pilmore, H., McGinn, S., Krishnan, A., Teixeira-Pinto, A., Kieu, A., Ng, O., & Wong, G. (2025). Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre‐exposure COVID‐19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients. Internal Medicine Journal. https://doi.org/10.1111/imj.70179
Vancouver
Lim WH, Wang J, Pilmore H, McGinn S, Krishnan A, Teixeira-Pinto A, et al. Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre‐exposure COVID‐19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients. Internal Medicine Journal. 2025. doi:10.1111/imj.70179
BibTeX
@article{Lim2025,
author = {Lim, Wai H and Wang, Jiayue and Pilmore, Helen and McGinn, Stella and Krishnan, Anoushka and Teixeira-Pinto, Armando and Kieu, Anh and Ng, Owen and Wong, Germaine},
title = {Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre‐exposure COVID‐19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.70179}
}
EUVIMED